Establishment of a 5-gene risk model related to regulatory T cells for predicting gastric cancer prognosis.
Gastric cancer
Prognosis prediction
Regulatory T cells
TCGA
mRNA signature
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
11
2019
accepted:
18
08
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
11
9
2020
Statut:
epublish
Résumé
Gastric cancer (GC) is one of the high-risk cancers that lacks effective methods for prognosis prediction. Therefore, we searched for immune cells related to the prognosis of GC and studied the role of related genes in GC prognosis. In this study, we collected the mRNA data of GC from The Cancer Genome Atlas (TCGA) database and studied the immune cells that were closely related to the prognosis of GC. Spearman correlation analysis was performed to show the association between immune cell-related genes and the differentially expressed genes (DEGs) of GC. Univariate and multivariate Cox regression analyses were conducted on the immune cell-related genes with a high correlation with GC. A prognostic risk score model was constructed and the most significant feature genes were identified. Kaplan-Meier method was then used to compare the overall survival (OS) of patients with high-risk and low-risk, and receiver operating characteristic (ROC) analysis was used to assess the accuracy of the risk model. In addition, GC patients were grouped according to the median expression of the features genes, and survival analysis was further carried out. It was noted that regulatory T cells (Tregs) were significantly correlated with the prognosis of GC, and 172 genes related to Tregs were found to be closely associated with GC. An optimal prognostic risk model was constructed, and a 5-gene (including LRFN4, ADAMTS12, MCEMP1, HP and MUC15) signature-based risk score was established. Survival analysis showed significant difference in OS between low-risk and high-risk samples. ROC analysis results indicated that the risk model had a high accuracy for the prognosis prediction of samples (AUC = 0.717). The results of survival analysis on each feature gene based on expression levels were consistent with the results of multivariate Cox analysis for predicting the risk rate of the 5 genes. These results proved that the 5-gene signature-based risk score could be used to predict the survival of GC patients, and these 5 genes were closely related to Tregs. These findings are of great significance for studying the role of immune cells and related immune factors in regulating the prognosis of GC.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric cancer (GC) is one of the high-risk cancers that lacks effective methods for prognosis prediction. Therefore, we searched for immune cells related to the prognosis of GC and studied the role of related genes in GC prognosis.
METHODS
METHODS
In this study, we collected the mRNA data of GC from The Cancer Genome Atlas (TCGA) database and studied the immune cells that were closely related to the prognosis of GC. Spearman correlation analysis was performed to show the association between immune cell-related genes and the differentially expressed genes (DEGs) of GC. Univariate and multivariate Cox regression analyses were conducted on the immune cell-related genes with a high correlation with GC. A prognostic risk score model was constructed and the most significant feature genes were identified. Kaplan-Meier method was then used to compare the overall survival (OS) of patients with high-risk and low-risk, and receiver operating characteristic (ROC) analysis was used to assess the accuracy of the risk model. In addition, GC patients were grouped according to the median expression of the features genes, and survival analysis was further carried out.
RESULTS
RESULTS
It was noted that regulatory T cells (Tregs) were significantly correlated with the prognosis of GC, and 172 genes related to Tregs were found to be closely associated with GC. An optimal prognostic risk model was constructed, and a 5-gene (including LRFN4, ADAMTS12, MCEMP1, HP and MUC15) signature-based risk score was established. Survival analysis showed significant difference in OS between low-risk and high-risk samples. ROC analysis results indicated that the risk model had a high accuracy for the prognosis prediction of samples (AUC = 0.717). The results of survival analysis on each feature gene based on expression levels were consistent with the results of multivariate Cox analysis for predicting the risk rate of the 5 genes.
CONCLUSION
CONCLUSIONS
These results proved that the 5-gene signature-based risk score could be used to predict the survival of GC patients, and these 5 genes were closely related to Tregs. These findings are of great significance for studying the role of immune cells and related immune factors in regulating the prognosis of GC.
Identifiants
pubmed: 32908454
doi: 10.1186/s12935-020-01502-6
pii: 1502
pmc: PMC7470613
doi:
Types de publication
Journal Article
Langues
eng
Pagination
433Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestThe authors declare no conflicts of interest.
Références
J Thorac Oncol. 2018 Apr;13(4):521-532
pubmed: 29269008
Ann Oncol. 2018 Mar 1;29(3):542-543
pubmed: 29360923
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Oncotarget. 2016 Apr 26;7(17):24269-83
pubmed: 27009855
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancers (Basel). 2020 Jun 01;12(6):
pubmed: 32492934
Cancer Res. 2011 May 15;71(10):3505-15
pubmed: 21444674
World J Gastroenterol. 2014 Feb 21;20(7):1635-49
pubmed: 24587643
Gastroenterol Clin North Am. 2013 Jun;42(2):219-40
pubmed: 23639638
J Oral Pathol Med. 2020 Jan;49(1):49-54
pubmed: 31478236
Cancer Res Treat. 2020 May 04;:
pubmed: 32599987
FEBS Lett. 2011 Jul 21;585(14):2377-84
pubmed: 21704618
Gastroenterol Clin North Am. 2013 Jun;42(2):359-69
pubmed: 23639645
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Oncogenesis. 2018 Nov 12;7(11):85
pubmed: 30420637
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Cancer Immunol Immunother. 2005 Nov;54(11):1072-81
pubmed: 15959774
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855
pubmed: 30482962
Urology. 2003 Dec;62(6):1012-7
pubmed: 14665346
Dig Dis Sci. 2011 Nov;56(11):3281-7
pubmed: 21559743
Arch Pathol Lab Med. 2016 Mar;140(3):249-54
pubmed: 26927720
Arch Pathol Lab Med. 2016 Apr;140(4):326-31
pubmed: 26756647
World J Gastroenterol. 2019 Aug 21;25(31):4452-4467
pubmed: 31496624
Eur J Cancer. 2008 May;44(7):946-53
pubmed: 18396036
J Carcinog. 2014 Dec 19;13:14
pubmed: 25589897
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
J Cancer. 2019 Jun 2;10(12):2754-2763
pubmed: 31258783
Cancer Res Treat. 2020 May 08;:
pubmed: 32599985
Onco Targets Ther. 2019 Aug 09;12:6275-6284
pubmed: 31496731
Mol Cancer. 2020 Jun 29;19(1):112
pubmed: 32600329
Lancet Oncol. 2013 May;14(6):490-9
pubmed: 23594786
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Asian Pac J Cancer Prev. 2015;16(12):4821-4
pubmed: 26163597